Paxlovid was in high demand when Pfizer made it broadly available during the delta and omicron pandemic waves ... Her ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus.

About 8 in 10 infants received respiratory syncytial virus protection during the 2023 to 2024 season, according to study findings.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

据外媒新闻，美国FDA要求辉瑞和葛兰素史克（GSK）生产的呼吸道合胞病毒（RSV）疫苗须在标签上增加有关罹患吉兰-巴雷综合征（GBS）风险的警告。吉兰-巴雷综合征是一种罕见的神经系统疾病，其病因可能与感染和免疫反应有关，特征性症状为对称性的肢体无力、 ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...